FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
Proceeds will accelerate the clinical development of plixorafenib, the company’s novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations Matthew E. Ros will...